Erythropoietin, epoetins and detection;Eritropoetin, epoetini in njihova detekcija

Farmacevtski Vestnik

Volumn 60, Issue 5, 2009, Pages 279-285

  Španinger, Klemen ^a   Debeljak, Nataša ^a  

^a UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; DENSITOMETRY; DOPING; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG MECHANISM; DRUG URINE LEVEL; ELECTROPHORESIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HORMONE ACTION; HORMONE RECEPTOR INTERACTION; HORMONE STRUCTURE; HUMAN; ISOELECTRIC FOCUSING; KIDNEY FAILURE; NONHUMAN; QUALITY OF LIFE; REVIEW;

EID: 71849109597     PISSN: 00148229     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Segura J, Pascual JA, Gutierrez-Gallego R. Procedures for monitoring recombinant erythropoietin and analogues in doping control. Anal Bioanal Chem 2007; 388(7): 1521-1529
2. Maxwell PH, Ferguson DJ, Nicholls LG et al. Sites of erythropoietin production. Kidney Int 1997; 51(2): 393-401.
3. Thorling EB, Erslev AJ. The "tissue" tension of oxygen and its relation to hematocrit and erythropoiesis. Blood 1968; 31(3): 332-343
4. Jelkmann W. Erythropoietin: structure, control of production, and function. Physiol Rev 1992; 72(2): 449-489
5. Romanowski RR, Sytkowski AJ. The molecular structure of human erythropoietin. Hematol Oncol Clin North Am 1994; 8(5): 885-894
6. Jelkmann W. Molecular biology of erythropoietin. Intern Med 2004; 43(8): 649-659
7. Stockmann C, Fandrey J. Hypoxia-induced erythropoietin production: a paradigm for oxygen-regulated gene expression. Clin Exp Pharmacol Physiol 2006; 33(10): 968-979
8. Jelkmann W. Control of erythropoietin gene expression and its use in medicine. Methods Enzymol 2007; 435: 179-197
9. Bunn HF. New agents that stimulate erythropoiesis. Blood 2007; 109(3): 868-873
10. Adamson JW. Regulation of red blood cell production. Am J Med 1996; 101(2A): 4S-6S.
11. Pascual JA, Belalcazar V, de Bolos C, Gutierrez R, Llop ESegura J. Recombinant erythropoietin and analogues: a challenge for doping control. Ther Drug Monit 2004; 26(2): 175-179
12. Debeljak N, Sytkowski AJ, EpoR. UCSD-Nature Molecule Pages 2007: A000863. 2007.
13. Arcasoy MO. The non-haematopoietic biological effects of erythropoietin. Br J Haematol 2008; 141(1): 14-31.
14. Watowich SS. Activation of erythropoietin signaling by receptor dimerization. The International Journal of Biochemistry & Cell Biology 1999; 31(10): 1075-1088. (Pubitemid 29454547)
15. Livnah O, Stura EA, Middleton SA, Johnson DL, Jolliffe LK, Wilson IA. Crystallographic Evidence for Preformed Dimers of Erythropoietin Receptor Before Ligand Activation. Science 1999; 283(5404): 987-990.
16. Skibeli V, Nissen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood 2001; 98(13): 3626-3634
17. Debeljak N, Sytkowski AJ. Erythropoietin: new approaches to improved molecular designs and therapeutic alternatives. Curr Pharm Des 2008; 14(13): 1302-1310
18. Halstenson CE, Macres M, Katz SA et al. Comparative pharmacokinetics and pharmacodynamics of epoetin alfa and epoetin beta. Clin Pharmacol Ther 1991; 50(6): 702-712
19. Veys N, Dhondt A, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin: phosphate-buffered epoetin alpha compared to citrate-buffered epoetin alpha and epoetin beta. Clin Nephrol 1998; 49(1): 41-44
20. Veys N, Vanholder R, Lameire N. Pain at the injection site of subcutaneously administered erythropoietin in maintenance hemodialysis patients: a comparison of two brands of erythropoietin. Am J Nephrol 1992; 12(1-2): 68-72.
21. Egrie JC, Browne JK. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol Dial Transplant 2001; 16 Suppl 3: 3-13. (Pubitemid 32591159)
22. Locatelli F, Olivares J, Walker R et al. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001; 60(2): 741-747
23. Gaudard A, Varlet-Marie E, Bressolle F, Audran M. Drugs for increasing oxygen and their potential use in doping: a review. Sports Med 2003; 33(3): 187-212.
24. Bren A, Kandus A, Varl J et al. A comparison between epoetin omega and epoetin alfa in the correction of anemia in hemodialysis patients: a prospective, controlled crossover study. Artif Organs 2002; 26(2): 91-97 (Pubitemid 34225203)
25. Lasne F, Thioulouse J, Martin L, de Ceaurriz J. Detection of recombinant human erythropoietin in urine for doping analysis: interpretation of isoelectric profiles by discriminant analysis. Electrophoresis 2007; 28(12): 1875-1881
26. Lasne F. Double-blotting: a solution to the problem of non-specific binding of secondary antibodies in immunoblotting procedures. J Immunol Methods 2001; 253(1-2): 125-131 (Pubitemid 32522520)
27. Lasne F, Martin L, Martin J, Ade Ceaurriz J. Isoelectric profiles of human erythropoietin are different in serum and urine. Int J Biol Macromol 2007; 41(3): 354-357 (Pubitemid 46990535)
28. van de Pol SMG, Doornaert PAH, de Bree R, Leemans CRxe, Slotman B, JLangendijk JA. The significance of anemia in squamous cell head and neck cancer treated with surgery and postoperative radiotherapy. Oral Oncology; In Press, Corrected Proof.
29. Azzazy HME, Mansour MMH, Christenson RH. Doping in the recombinant era: Strategies and counterstrategies. Clinical Biochemistry 2005; 38(11): 959-965.
30. Gurney CW, Wackman N, Filmanowicz E. Studies on erythropoiesis. XVII. Some quantitative aspects of the erythropoietic response to erythropoietin. Blood 1961; 17: 531-546
31. Goldberg MA. Erythropoiesis, erythropoietin, and iron metabolism in elective surgery: preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 1995; 170(6A Suppl): 37S-43S.
32. Dunn CJ, Markham A. Epoetin beta. A review of its pharmacological properties and clinical use in the management of anaemia associated with chronic renal failure. Drugs 1996; 51(2): 299-318. (Pubitemid 26039161)
33. Belalcazar V, Gutierrez Gallego R, Llop E, Segura J, Pascual JA. Assessing the instability of the isoelectric focusing patterns of erythropoietin in urine. Electrophoresis 2006; 27(22): 4387-4395
34. Wilber RL. Detection of DNA-recombinant human epoetin-alfa as a pharmacological ergogenic aid. Sports Med 2002; 32(2): 125-142
35. Bohlius J, Wilson J, Seidenfeld J et al. Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 2006; 98(10): 708-714 (Pubitemid 43821788)
36. Leyland-Jones B. Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003; 4(8): 459-460
37. Leyland-Jones B, Semiglazov V, Pawlicki M et al. Maintaining Normal Hemoglobin Levels With Epoetin Alfa in Mainly Nonanemic Patients With Metastatic Breast Cancer Receiving First-Line Chemotherapy: A Survival Study. J Clin Oncol 2005; 23(25): 5960-5972. (Pubitemid 46300213)
38. Henke M, Laszig R, Rube C et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003; 362(9392): 1255-1260
39. Machtay M, Pajak TF, Suntharalingam M et al. Radiotherapy With or Without Erythropoietin for Anemic Patients With Head and Neck Cancer: A Randomized Trial of the Radiation Therapy Oncology Group (RTOG 99-03). International Journal of Radiation Oncology*Biology*Physics 2007; 69(4): 1008-1017. (Pubitemid 47625834)